Eli Lilly (India) announced on Tuesday that it has received marketing approval from India's Central Drugs Standard Control Organization for donanemab, a drug used to treat Alzheimer's disease.

The approval specifically covers patients in the early symptomatic stages of Alzheimer's, including those with mild cognitive impairment and mild dementia. Treatment with donanemab requires confirmation of amyloid pathology in patients.

This regulatory approval makes India one of the markets where Eli Lilly can distribute its Alzheimer's treatment drug.